This synergistic cluster of CI<0.7 also included previously described combination strategies in cancer therapy regardless of KRAS status, such as the combination of topoisomerase inhibitors with tyrosine kinase inhibitors42, 43 or mTOR inhibitors44 in different cancer models. The gene discussed is KRAS; the disease is cancer.